imatinib mesylate has been researched along with Crohn Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agud Fernández, M; Díaz Pedroche, C; Gómez-Martín, C; López López, F | 1 |
| Costa, C; Magro, F | 1 |
2 other study(ies) available for imatinib mesylate and Crohn Disease
| Article | Year |
|---|---|
Concurrent inflammatory bowel disease and gastrointestinal stromal tumor.
Topics: Aged, 80 and over; Combined Modality Therapy; Crohn Disease; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Ileal Neoplasms; Imatinib Mesylate; Immunosuppressive Agents; Intestinal Obstruction; Intestinal Pseudo-Obstruction; Jejunal Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Sunitinib | 2018 |
Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease.
Topics: Adolescent; Benzamides; Blood Sedimentation; Crohn Disease; Female; Humans; Imatinib Mesylate; Piperazines; Platelet Count; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome; Treatment Refusal | 2006 |